Elizabeth Ditty

Mersana Therapeutics (United States) — United States

Medicine · Health Sciences

6h-index122citations49works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Radiopharmaceutical Chemistry and Applications(24), interferon and immune responses(16), HER2/EGFR in Cancer Research(15), Neuroblastoma Research and Treatments(14), Chemical Synthesis and Analysis(12)

Publications49 total

Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
2025Open Access
Supplementary Figure S3 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S1 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S7 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S4 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S1 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Data from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S2 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S4 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S2 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S6 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S5 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S8 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S3 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Clinical Cancer Research·2025· 20 citedOpen Access
Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
2024Open Access
Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
2024Open Access
Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
2024Open Access
Table S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
Table S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024Open Access
page 1 of 3Next →

Frequent Co-authors

Dorin Toader(49), Marc Damelin(49), Timothy B. Lowinger(49), Kalli C. Catcott(48), Ling Xu(44), Jeffrey Zurita(40), Kelly L. Lancaster(36), Bingfan Du(34), LiuLiang Qin(34), Stephen P. Bradley(32), David H. Lee(31), Scott D. Collins(27), Susan M. Clardy(27), Jeremy R. Duvall(25), Alex Uttard(25), Kenneth Avocetien(25), Caitlin Routhier(24), Pamela Shaw(24), Tyler Carter(23), Mark Nazzaro(23)